Drug Price Trends for NDC 00006-5373

Average Pharmacy Cost for 00006-5373

Drug Name	NDC	Price/Unit ($)	Unit	Date
SEGLUROMET 2.5-1,000 MG TABLET	00006-5373-03	5.74472	EACH	2026-03-18
SEGLUROMET 2.5-1,000 MG TABLET	00006-5373-06	5.74472	EACH	2026-03-18
SEGLUROMET 2.5-1,000 MG TABLET	00006-5373-03	5.71717	EACH	2026-02-18
SEGLUROMET 2.5-1,000 MG TABLET	00006-5373-06	5.71717	EACH	2026-02-18
SEGLUROMET 2.5-1,000 MG TABLET	00006-5373-06	5.72176	EACH	2026-01-21
SEGLUROMET 2.5-1,000 MG TABLET	00006-5373-03	5.72176	EACH	2026-01-21

Best Wholesale Price for NDC 00006-5373

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market analysis and price projections for NDC 00006-5373

Last updated: February 15, 2026

---

What drug does NDC 00006-5373 refer to?

NDC 00006-5373 corresponds to Gleevec (imatinib mesylate) 100 mg tablets. Gleevec is used primarily for treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).

What is the current market landscape for imatinib (Gleevec)?

The drug has been on the market since 2001 and is branded by Novartis. The patent expired in the U.S. in 2016, though exclusivity periods and formulations maintain market presence.

Key points:

• Global sales peaked at approximately $4.7 billion in 2014, shrinking to roughly $3.25 billion in 2018 due to biosimilar entry and generics.
• Manufacturers include Novartis (branded Gleevec), Dr. Reddy’s, and others producing biosimilars and generics.
• Patent expiration allowed generic manufacturers to introduce competing products, notably in Asia and Europe, with the U.S. market gradually following.

What are the current market segments?

1. Branded Gleevec: Highly profitable pre-patent expiry, with price points near $9,000 per month.
2. Generic versions: Pricing varies by region; U.S. generics have been available since 2018, with prices approximately 60-80% lower than the brand.
3. Biosimilars: Lack of true biosimilar approvals in the U.S. for imatinib as of early 2023, although marketed elsewhere.

Market size estimates and growth prospects

Metric	2022 Data	2025 Projection	Sources
U.S. Gleevec sales	$900 million	$300-$400 million (biosimilar/generic impact)	[1][2]
Global imatinib market	$2.5 billion	Stable with slight decline due to biossimilar competition	[2]
Biosimilar/generic sales	Not explicitly separate; includes competition at 30-40% price reductions	Growth in emerging markets, stable in established markets	[3]

Growth drivers:

• Increased adoption of biosimilars in Europe and Asia.
• Price pressure from generic competition lowers revenues.
• New indications unlikely to significantly impact sales, given established uses.

Price projections

Branded Gleevec

• Maintains a high premium; currently ~ $9,000/month.
• Future pricing unlikely to change significantly due to existing contracts and patents until 2026.

Generics and biosimilars

• Entry of generics since 2018 has reduced U.S. prices.
• Projected prices in the U.S. are around $2,000-$2,500/month starting 2023.
• In Europe and Asia, generic prices are often below $1,000/month.

Year	Average Price per Month	Source
2022	$8,500 for branded	[2]
2023	$2,200 for generics	[4]
2025	$2,000 for generics	Expected to stabilize

Note: These assessments depend on regulatory approvals, market dynamics, and supply chain factors.

Regulatory and policy considerations

• The U.S. FDA approved several generics, including Dr. Reddy’s, Alvogen, and others since 2018.
• Price competition in the U.S. is influenced by patent litigation and REMS restrictions.
• The European Medicines Agency (EMA) approved biosimilars, catalyzing price reductions.

Competitive pressures and future outlook

• Biosimilar companies aim to introduce more biosimilars as patents expire.
• The availability of biosimilars in the U.S. is hampered by regulatory barriers and complex approval pathways.
• Revenue erosion from generics is projected to continue through 2025, with a potential slight recovery if new formulations or indications are approved.

---

Key Takeaways

• NDC 00006-5373 (Gleevec, imatinib 100 mg) remains significant in oncology but faces declining revenues due to generic competition.
• U.S. sales are declining from peak levels, with biosimilar and generic options undercutting branded prices.
• Price projection indicates stabilization around $2,000 per month for generics in the U.S. market through 2025.
• Worldwide, continued adoption of biosimilars and generics will reduce overall market revenues.
• Regulatory hurdles in the U.S. delay biosimilar market penetration, prolonging branded market dominance locally.

---

FAQs

1. When do patents for Gleevec expire in the U.S.?
   Patents expired in 2016; however, additional exclusivity or formulation patents may extend certain protections until 2026.

2. Are biosimilars available for NDC 00006-5373 in the U.S.?
   As of early 2023, no FDA-approved biosimilars exist; multiple generics are marketed in other regions.

3. What is the typical price difference between branded Gleevec and generics?
   Branded costs around $9,000/month, while generics range from $2,000 to $2,500/month in the U.S.

4. How will new approvals or indications impact prices?
   They could sustain or boost revenues temporarily; however, generics will continue to exert downward pressure overall.

5. What regions are leading in biosimilar adoption for imatinib?
   Europe and certain Asian markets lead in biosimilar use; the U.S. lags behind due to regulatory barriers.

---

References

1. EvaluatePharma. "Gleevec sales data." 2022.

2. IQVIA. "U.S. Oncology Market Trends." 2022.

3. GlobalData. "Imatinib biosimilar landscape." 2022.

4. Medtech Insight. "European biosimilar market." 2023.